Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its ...

Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.

Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.

A recent CNN report cast a spotlight on Akeso, a Chinese biotech company whose immunotherapy ivonescimab drug, now in ...